Pqe80 plasmid

Manufactured by Qiagen

The PQE80 plasmid is a vector used for the expression of recombinant proteins in Escherichia coli. It contains a T5 promoter and a His-tag sequence for the purification of the expressed proteins.

Automatically generated - may contain errors

Lab products found in correlation

Biologic duoflow chromatography system, by Bio-Rad (2 mentions) Pd 10 desalting column, by GE Healthcare (2 mentions) P azido l phenylalanine azf, by Chem-Impex (2 mentions) Uno q1 anion exchange column, by Bio-Rad (2 mentions) Ni nta agarose, by Qiagen (2 mentions) Sequencing grade modified trypsin, by Promega (2 mentions) Vivaspin centrifugal concentrator, by Sartorius (2 mentions) C18 ziptip, by Merck Group (1 mentions) Superdex 200 10 300 gl size exclusion column, by GE Healthcare (1 mentions) Ziptip with c18 resin, by Merck Group (1 mentions) Hitrap sp hp cation exchange column, by GE Healthcare (1 mentions)

Spelling variants of this product

PQE80 (9 citations)

2 protocols using pqe80 plasmid

Site-Specific Protein Labeling Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

DBCO-PEG₄-carboxyrhodamine 110, DBCO-amine, TCO-NHS ester, and tetrazine-DBCO were purchased from Bioconjugate Technology Company (Scottsdale, AZ). p-Azido-L-phenylalanine (AZF) was purchased from Chem-Impex International (Wood Dale, IL) and dissolved in 0.2 M sodium hydroxide to prepare 100 mM stock solution. Ni-NTA agarose and pQE80 plasmid were obtained from Qiagen (Valencia, CA). Vivaspin centrifugal concentrators with a MWCO of 50 kDa were obtained from Sartorius Corporation (Bohemia, NY). ZipTip C18 was purchased from Millipore Corporation (Billerica, MA). Sequencing-grade modified trypsin was obtained from Promega Corporation (Madison, WI). PD-10 desalting columns and Superdex 200 10/300 GL sized exclusion column were obtained from GE Healthcare (Piscataway, NJ). UNO Q1 anion exchange column and Biologic DuoFlow chromatography system were obtained from Bio-Rad (Hercules, CA). All chemicals were obtained from Sigma-Aldrich Corporation (St. Louis, MO) unless otherwise stated.

Lim S.I., Yang B., Jung Y., Cha J., Cho J., Choi E.S., Kim Y.H, & Kwon I. (2016). Controlled Orientation of Active Sites in a Nanostructured Multienzyme Complex. Scientific Reports, 6, 39587.

+ Open protocol

+ Expand

Bioconjugation of Proteins with AzF

Check if the same lab product or an alternative is used in the 5 most similar protocols

p-Azido-l-phenylalanine (AzF) was obtained from Chem-Impex International (Wood Dale, IL) and dissolved in 0.2 M NaOH to make 100 mM stock solution. Ni-NTA agarose and pQE80 plasmid were obtained from Qiagen (Valencia, CA). Vivaspin centrifugal concentrators with a MWCO of 50 kDa were purchased from Sartorius Corporation (Bohemia, NY). ZipTip with C18 resin was purchased from Millipore Corporation (Billerica, MA). Sequencing grade modified trypsin was obtained from Promega Corporation (Madison, WI). DBCO-PEG₄-carboxyrhodamine, DBCO-PEG₄-MAL, and DBCO-PEG₄-DBCO were purchased from Bioconjugate Technology Company (Scottsdale, AZ). 15-Azidopentadecanoic acid was obtained from Life Technologies (Gaithersburg, MD). PD-10 desalting columns, HiTrap SP HP cation exchange column, and Superdex 200 10/300 GL size exclusion column were obtained from GE Health care (Piscataway, NJ). UNO Q1 anion exchange column and Biologic DuoFlow chromatography system were obtained from Bio-Rad (Hercules, CA). All chemicals were obtained from Sigma-Aldrich Corporation (St. Louis, MO) unless otherwise stated.

Lim S.I., Hahn Y.S, & Kwon I. (2015). Site-specific albumination of a therapeutic protein with multi-subunit to prolong activity in vivo. Journal of controlled release : official journal of the Controlled Release Society, 207, 93-100.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!